JOURNAVX (suzetrigine)
SUZETRIGINE · ACUTE PAIN
VERTEX PHARMACEUTICAL
Drug class
suzetrigine
Suzetrigine is a specific active drug ingredient rather than an established therapeutic class name, though it represents a first-in-class selective voltage-gated sodium channel 1.8 (NaV1.8) inhibitor. Read more about suzetrigine
1 drugs in this class 1 manufacturers
Drugs in suzetrigine
Filter & compare in the drug finder →
Opens the drug finder with suzetrigine preselected. Add indication or manufacturer filters there.
Suzetrigine is a specific active drug ingredient rather than an established therapeutic class name, though it represents a first-in-class selective voltage-gated sodium channel 1.8 (NaV1.8) inhibitor.
As a non-opioid peripheral pain signal inhibitor, it selectively blocks NaV1.8 channels highly concentrated in peripheral nociceptive sensory neurons, thereby halting action potential propagation and pain transmission to the central nervous system without producing opioid-related central side effects or addiction risks.
It is indicated for the treatment of moderate-to-severe acute pain in adult patients, with investigational applications extending into neuropathic pain conditions such as diabetic peripheral neuropathy.
-
fda.gov
Suzetrigine is a specific active drug ingredient rather than an established therapeutic class name, though it represents a first-in-class selective voltage-gated sodium channel 1.8 (NaV1.8) inhibitor It is indicated for the treatment of moderate-to-severe acute pain in adult patients, with investigational applications extending into neuropathic pain conditions such as diabetic peripheral neuropathy
-
fda.gov
Suzetrigine is a specific active drug ingredient rather than an established therapeutic class name, though it represents a first-in-class selective voltage-gated sodium channel 1.8 (NaV1.8) inhibitor
-
vrtx.com
As a non-opioid peripheral pain signal inhibitor, it selectively blocks NaV1.8 channels highly concentrated in peripheral nociceptive sensory neurons, thereby halting action potential propagation and pain transmission to the central nervous system without producing opioid-related central side effects or addiction risks
-
nih.gov
As a non-opioid peripheral pain signal inhibitor, it selectively blocks NaV1.8 channels highly concentrated in peripheral nociceptive sensory neurons, thereby halting action potential propagation and pain transmission to the central nervous system without producing opioid-related central side effects or addiction risks It is indicated for the treatment of moderate-to-severe acute pain in adult patients, with investigational applications extending into neuropathic pain conditions such as diabetic...
-
nih.gov
As a non-opioid peripheral pain signal inhibitor, it selectively blocks NaV1.8 channels highly concentrated in peripheral nociceptive sensory neurons, thereby halting action potential propagation and pain transmission to the central nervous system without producing opioid-related central side effects or addiction risks
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.